ICD-10 Code for PSA Testing
For ordering a PSA test, use ICD-10 code Z12.5 (Encounter for screening for malignant neoplasm of prostate) for asymptomatic screening, or R97.20 (Elevated prostate specific antigen [PSA]) for follow-up of abnormal results.
Primary Screening Codes
When ordering PSA testing for prostate cancer screening in asymptomatic men, the appropriate code is:
- Z12.5: Encounter for screening for malignant neoplasm of prostate
This code should be used when:
- The patient has no symptoms of prostate disease
- No prior diagnosis of prostate cancer exists
- The test is being performed as part of routine screening per guideline recommendations 1, 2
Alternative Diagnostic Codes
For non-screening scenarios, consider these codes:
- R97.20: Elevated prostate specific antigen (PSA) - use for follow-up of previously elevated PSA
- N40.0: Benign prostatic hyperplasia without lower urinary tract symptoms - if ordering PSA for BPH monitoring
- N40.1: Benign prostatic hyperplasia with lower urinary tract symptoms - if patient has obstructive urinary symptoms
- Z85.46: Personal history of malignant neoplasm of prostate - for surveillance after prostate cancer treatment
Clinical Context for Code Selection
Research demonstrates that PSA tests fall into distinct categories that should guide your coding choice 3:
- Pure screening (19% of tests): Asymptomatic patients with no urinary symptoms → use Z12.5
- Symptomatic screening (46% of tests): Patients with obstructive urinary symptoms → use N40.1 or N40.0
- Diagnostic testing (35% of tests): Follow-up of abnormal results or known disease → use R97.20 or other specific codes
Important Coding Pitfalls
Avoid using symptom codes when performing true screening, as this may:
- Affect insurance coverage and reimbursement
- Misrepresent the clinical indication
- Impact quality metrics and screening statistics
Do not use Z12.5 if the patient has:
- Current urinary symptoms (use symptom-specific codes)
- Known prostate cancer (use Z85.46 for surveillance)
- Previously elevated PSA requiring follow-up (use R97.20)
Screening Guidelines Context
Current evidence shows PSA screening likely reduces prostate cancer-specific mortality (Rate Ratio 0.87,95% CI 0.80-0.95) 4, supporting the use of screening codes in appropriate populations. Guidelines recommend shared decision-making for men ages 55-69 years 2, with consideration for earlier screening in high-risk populations including African American men and those with family history 1.